DAPT Study
Risk ClinicalTrial.gov

WELCOME

The DAPT Study was an independent, large-scale study in size and scope intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication to reduce the risk of blood clots) to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents.

The DAPT Study was an international initiative that was developed by a group of eight manufacturers (four major stent manufacturers and four manufacturers of antiplatelet medications) who came together to address a U.S. Food and Drug Administration (FDA) request for this post-market study. The Baim Institute for Clinical Research (www.baiminstitute.org) was responsible for the scientific conduct and independent analysis of the overall study.

The study assessed the benefits of 12 versus 30 months of dual antiplatelet therapy for preventing stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) in subjects undergoing percutaneous coronary intervention (PCI) with drug-eluting stent placement for the treatment of coronary artery lesions.
Final results from the DAPT Study showed that continued thienopyridine therapy beyond one year is beneficial in patients who have received DES and tolerated one year of dual antiplatelet therapy. These benefits were present for all stent and drug types studied and were consistent regardless of patient characteristics.
While patients who have risks of major bleeding or who have reduced life expectancy for other reasons may not benefit, the study investigators believe that the overall benefits of continuing dual antiplatelet therapy to 30 months after coronary stenting outweigh the bleeding risks and that these results warrant a shift in clinical practice towards longer-duration treatment in most patients.

More information on the DAPT Study can be found in the New England Journal of Medicine, and subsequent publications.